PteroActiv was designed to be utilized by both medical researchers needing a highly purified source of pterostilbene for human clinical trials, and also for informed consumers interested in taking advantage of the potential health effects of this remarkable molecule.
Resveratrol grabbed the attention of the medical community and the international scientific press after Dr. Sinclair’s Harvard Medical School study was published in the Journal, Nature, in 2006. Its health properties have been substantiated by hundreds of medical researchers whose studies have been published in over 4,500 peer-reviewed animal, in vitro, and human clinical trials and studies.
Pterostilbene is closely related to resveratrol, and complements resveratrol by strongly activating various genes, proteins, and signaling pathways, that resveratrol only weakly activates or does not affect at all. Pterostilbene provides a more comprehensive range of health and fitness benefits than resveratrol alone.
Biotivia will soon announce a large scale human clinical trial of their Pterostilbene supplement. This study will be undertaken by a large European medical school, and will investigate the ability of Pterostilbene to stop or possibly even reverse the progress of a common but fatal organ disease for which there exists no current pharmaceutical treatment. Transmax resveratrol will also be used in place of PteroActiv with one half of the patients to compare the relative effectiveness of the two compounds.
To read more about resveratrol and pterostilbene visit Biotivia
About Biotivia LLC
Biotivia was established in 1992 in Vienna, Austria as a supplier of natural raw materials and biologically active botanics to the supplement and functional food industries and to researchers and scientific institutions worldwide. The company evolved into one of the world’s leading developers and suppliers of unique science-based nutritional supplements and award winning skin care therapies, with most of their products centered around the use of concentrated resveratrol and complementary botanical extracts.
Biotivia presently has US offices in New York, Los Angeles, Kansas City and international offices in the UK, Spain, Austria, Denmark, Italy, Germany, Singapore, Xi’an, China and Mumbai, India.
Beyond its strong consumer base, the company currently supplies researchers, physicians and scientists at Harvard, Stanford, Yale, Georgetown, The Albert Einstein Medical Center, University of Texas, M.D. Anderson Cancer Center, Health Canada, and the University of California. Transmax and Bioforte in particular are being investigated by several major university medical schools as a possible treatment for a variety of conditions that seriously impair the health and well being of millions of people around the world. Biotivia most recently signed an agreement to supply Transmax to the University of Ferrara for use in three human clinical trials in Italy and Egypt on its possible use by Thalassemia sufferers as an alternative to the whole blood transfusions which such patients now require monthly. The Albert Einstein Medical College published a study which elucidated the beneficial effects of Biotivia’s proprietary resveratrol on glucose tolerance and mitochondria function in pre-diabetic subjects. Bioforte was also shown to more than double brain blood flow in a study done at the University of Northumbria in the UK.
Biotivia’s resveratrol products, Transmax and Bioforte, have been independently assessed by a leading American quality watchdog, and were deemed both ‘most potent’ and ‘best value’. Transmax has been certified as an investigational drug by the NIH, an endorsement of its safety and purity.
Most of Biotivia’s supplements have been certified Vegan by the American Vegetarian Association.
Important Caveat: Neither Bio Shape nor any Biotivia product has been definitively shown to diagnose, prevent or cure any age related diseases. Bio Shape is not intended to diagnose, prevent, treat or cure any disease. Studies done in vitro and on animals do not always translate into the same biological effect when taken by human subjects. The statements herein have not been reviewed or approved by the US FDA. All Biotivia supplements are manufactured in state of the art government inspected pharmaceutical facilities in accordance with CGMP and USP standards.
Other press releases from Biotivia Bioceuticals LLC
- Anti-diabetic potential of resveratrol shown in study - September 2nd, 2011
- Resveratrol Could Benefit Type 2 Diabetics - August 23rd, 2011
- PteroActiv, the new pterostilbene supplement from Biotivia - August 16th, 2011
- Bowel Disorders Can Be Eased With Probiotic Supplements - August 16th, 2011
- Resveratrol Is Good For The Brain - July 27th, 2011
Contact InformationLeo Day
Title: Marketing Consultant
Biotivia Bioceuticals LLC